116 related articles for article (PubMed ID: 6193340)
21. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
[TBL] [Abstract][Full Text] [Related]
22. [Comparative study of 5 alpha-reductase activity in the prostate and the human scalp].
Forastero MA; Bartolomé M; Mallol J
Arch Farmacol Toxicol; 1979 Dec; 5(3):238-40. PubMed ID: 94780
[No Abstract] [Full Text] [Related]
23. New histopathological experimental model for benign prostatic hyperplasia: stromal hyperplasia in rats.
Mori F; Oda N; Sakuragi M; Sakakibara F; Kiniwa M; Miyoshi K
J Urol; 2009 Feb; 181(2):890-8. PubMed ID: 19095262
[TBL] [Abstract][Full Text] [Related]
24. [Enzyme inhibition in the drug therapy of benign prostatic hyperplasia].
Drsata J
Cas Lek Cesk; 2002 Oct; 141(20):630-5. PubMed ID: 12515038
[TBL] [Abstract][Full Text] [Related]
25. Steroid 5-alpha reductase type 2 activity in biopsies from malignant and normal prostatic tissues.
Oliveira OL; Koff WJ; Muraro F; Santos EB; Gomes Soares DF; Trindade VM
Clin Chim Acta; 2008 May; 391(1-2):36-40. PubMed ID: 18328817
[TBL] [Abstract][Full Text] [Related]
26. Proceedings: The testosterone 5alpha-reductase of human hyperplastic prostate.
Wallace AM; Grant JK
J Endocrinol; 1975 Nov; 67(2):10P-11P. PubMed ID: 54402
[No Abstract] [Full Text] [Related]
27. Kinetic analysis of steroid 5alpha-reductase activity at neutral pH in benign prostatic hyperplastic tissue: evidence for type I isozyme activity in the human prostate.
Span PN; Benraad ThJ ; Sweep CG; Smals AG
J Steroid Biochem Mol Biol; 1996 Jan; 57(1-2):103-8. PubMed ID: 8645608
[TBL] [Abstract][Full Text] [Related]
28. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
29. A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia.
Sun ZY; Tu ZH
Methods Find Exp Clin Pharmacol; 1998 May; 20(4):283-7. PubMed ID: 9658376
[TBL] [Abstract][Full Text] [Related]
30. 5 alpha-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia.
Weisser H; Tunn S; Debus M; Krieg M
Steroids; 1994 Nov; 59(11):616-20. PubMed ID: 7535480
[TBL] [Abstract][Full Text] [Related]
31. 5 alpha-reductase activity in stroma and epithelium of rat prostate and epididymis. A contribution to elucidation of the mechanism for development of hyperplastic growth of prostatic tissue.
Djøseland O; Bruchovsky N; Rennie PS; Otal N; Høglo S
Acta Endocrinol (Copenh); 1983 Jun; 103(2):273-81. PubMed ID: 6190338
[TBL] [Abstract][Full Text] [Related]
32. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.
Titus MA; Gregory CW; Ford OH; Schell MJ; Maygarden SJ; Mohler JL
Clin Cancer Res; 2005 Jun; 11(12):4365-71. PubMed ID: 15958619
[TBL] [Abstract][Full Text] [Related]
33. Potential activities of androgen metabolizing enzymes in human prostate.
Krieg M; Weisser H; Tunn S
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):395-400. PubMed ID: 7542902
[TBL] [Abstract][Full Text] [Related]
34. 5alpha-reductase isozymes and androgen actions in the prostate.
Zhu YS; Imperato-McGinley JL
Ann N Y Acad Sci; 2009 Feb; 1155():43-56. PubMed ID: 19250191
[TBL] [Abstract][Full Text] [Related]
35. Prostatic hexosaminidase activity in patients with benign prostatic hyperplasia and prostatic carcinoma.
Whitehurst GB; Mashburn JP; Pretlow TG; Bradley EL; Boohaker EA
Cancer Res; 1982 Oct; 42(10):4300-3. PubMed ID: 6179600
[TBL] [Abstract][Full Text] [Related]
36. In vitro inhibition of androstenedione 5alpha-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia.
Weisser H; Krieg M
J Steroid Biochem Mol Biol; 1998 Oct; 67(1):49-55. PubMed ID: 9780029
[TBL] [Abstract][Full Text] [Related]
37. Selective non-steroidal inhibitors of 5 alpha-reductase type 1.
Occhiato EG; Guarna A; Danza G; Serio M
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):1-16. PubMed ID: 15026079
[TBL] [Abstract][Full Text] [Related]
38. Cell kinetic in epithelium and stroma of benign prostatic hyperplasia.
Claus S; Berges R; Senge T; Schulze H
J Urol; 1997 Jul; 158(1):217-21. PubMed ID: 9186363
[TBL] [Abstract][Full Text] [Related]
39. The distribution of 5 alpha-reductase and 3 alpha(beta)-hydroxysteroid dehydrogenase activities in the hyperplastic human prostate gland.
Habib FK; Beynon L; Chisholm GD; Busuttil A
Steroids; 1983 Jan; 41(1):41-53. PubMed ID: 6197780
[TBL] [Abstract][Full Text] [Related]
40. [Effect of estradiol, diethylstilbestrol, progesterone, and gestonorone capronate (depostat) on the 5 alpha-reductase kinetics in benign prostatic hypertrophy (BPH) (author's transl)].
Altwein JE; Rubin A; Klose K; Knapstein P; Orestano F
Urologe A; 1974 Jan; 13(1):41-6. PubMed ID: 4132876
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
